Hospital
Novant Health Rowan Medical Center LLC
Novant Health Rowan Medical Center LLC was paid $19.35M by Medicaid between Jan 2018 and Dec 2024, across 101 billing codes. Its largest line is 99283, emergency room visit (moderate) — 33% of everything it billed.
33Billing provider infoNOVANT HEALTH ROWAN MEDICAL CENTER LLC
SALISBURY, NC 28144
SALISBURY, NC 28144
33aNPI1508843566assigned 12/29/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$19.35M
24GClaims423,173
24DCodes billed101
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#32 of 92
Median peer was paid$11.47M
This provider vs. median1.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 57,903 | $2.03M | |
| 2019 | 70,443 | $2.18M | |
| 2020 | 50,671 | $1.89M | |
| 2021 | 52,318 | $2.41M | |
| 2022 | 53,908 | $3.23M | |
| 2023 | 61,853 | $3.33M | |
| 2024incomplete | 76,077 | $4.28M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 33% | 38,589 | 35,735 | $6.39M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 27% | 25,414 | 23,208 | $5.21M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.8% | 6,936 | 6,111 | $1.70M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 5.1% | 6,118 | 5,769 | $982K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.1% | 12,708 | 11,948 | $792K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.4% | 12,231 | 10,662 | $464K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.8% | 3,982 | 3,281 | $343K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 41,431 | 36,673 | $308K |
| 80053 | Comprehensive metabolic panel | 1.5% | 36,103 | 32,201 | $297K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 1,496 | 1,364 | $267K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 7,384 | 6,818 | $222K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 5,140 | 4,753 | $218K |
89 more codes
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 345 | $192K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,545 | $190K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,142 | $167K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 6,814 | $165K |
| J3490 | Unclassified drugs | <1% | 133,761 | $157K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,564 | $154K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,388 | $121K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,344 | $96K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,784 | $94K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,095 | $56K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 376 | $44K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 487 | $40K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,958 | $38K |
| 84484 | <1% | 3,758 | $37K | |
| 81001 | <1% | 11,011 | $36K | |
| D0220 | Intraoral - periapical first radiographic image | <1% | 214 | $35K |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 216 | $34K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,747 | $31K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,955 | $30K |
| G0378 | Hospital observation service, per hour | <1% | 840 | $28K |
| 81025 | <1% | 3,508 | $26K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,319 | $25K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,072 | $23K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 77 | $21K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 53 | $21K |
| 83690 | <1% | 2,673 | $21K | |
| 83735 | <1% | 3,369 | $21K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,394 | $20K |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 133 | $20K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,607 | $20K |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 92 | $15K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 49 | $13K |
| 88304 | <1% | 232 | $13K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 190 | $11K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,557 | $11K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,911 | $10K |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 45 | $8K |
| 87430 | <1% | 529 | $7K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 49 | $7K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 390 | $7K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 17 | $6K |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 90 | $6K |
| 84703 | <1% | 599 | $6K | |
| 87070 | <1% | 548 | $5K | |
| V2632 | Posterior chamber intraocular lens | <1% | 62 | $5K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 194 | $5K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 12 | $4K |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,200 | $4K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 209 | $4K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 131 | $3K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 26 | $3K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 481 | $3K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 137 | $2K |
| 81003 | <1% | 823 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 28 | $2K |
| 80299 | <1% | 120 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 405 | $2K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 76 | $1K |
| 87631 | <1% | 15 | $1K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 26 | $1K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 25 | $1K |
| 80143 | <1% | 34 | $1K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 50 | $1K |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 2,422 | $958.18 |
| 96367 | <1% | 25 | $628.80 | |
| C1769 | Guide wire | <1% | 15 | $535.72 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 30 | $517.54 |
| 80179 | <1% | 19 | $511.33 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 18 | $472.76 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12 | $411.49 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 12 | $411.43 |
| 87205 | <1% | 148 | $375.43 | |
| 87147 | <1% | 106 | $372.11 | |
| 87186 | <1% | 63 | $369.93 | |
| 97597 | <1% | 15 | $323.80 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 41 | $283.90 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 2,544 | $281.01 |
| 83880 | <1% | 17 | $253.80 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 15 | $224.41 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 13 | $206.30 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 12 | $164.67 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 15 | $155.80 |
| 87077 | <1% | 18 | $135.79 | |
| 84702 | <1% | 12 | $119.90 | |
| 85027 | <1% | 41 | $89.57 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 19 | $82.48 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 13 | $6.93 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 32 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 63 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBLABON, GARY (PRES/COO)
| Provider | Location | Paid |
|---|---|---|
| Novant Health Rowan Medical Center LLC | Salisbury, NC | $4.49M |
| Novant Health Rowan Medical Center LLC | Salisbury, NC | $65K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.